The US FDA has awarded orphan drug status to LBF Biotechnologies' anti-CD20 chimeric recombinant monoclonal antibody, currently known only as LFB-R603.
Thus far, LFB-R603's efficacy has only been demonstrated in vitro and in vivo, but has shown an especially strong cytotoxic effect against tumor cells expressing the CD20 antigen on their surfaces.
Currently, LFB is recruiting for a phase I study of LFB-R603.
CANCER TYPE(S)
Chronic lymphocytic leukemia
TREATMENT TYPE(S)
Monoclonal antibody
By Ross Bonander
Source
Medical News Today
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
